BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow up of 6 years (original) (raw)

Abstract

In this phase 2 multicenter trial, we evaluated the efficacy of the combination of bortezomib, dexamethasone and rituximab (BDR) in 59 previously untreated symptomatic patients with Waldenström's Macroglobulinemia, most of which were of advanced age and with adverse prognostic factors. BDR consisted of a single 21-day cycle of bortezomib alone (1.3 mg/m(2) IV days 1, 4, 8, and 11), followed by weekly IV bortezomib (1.6 mg/m(2) days 1, 8, 15, and 22) for 4 additional 35-day cycles, with IV dexamethasone (40 mg) and IV rituximab (375 mg/m(2)) on cycles 2 and 5, for a total treatment duration of 23 weeks. On intent to treat, 85% responded (3% complete response, 7% very good partial response, 58% partial response). After a minimum follow-up of 6 years, median progression-free survival was 43 months and median duration of response for patients with at least partial response was 64.5 months. Overall survival at 7 years was 66%. No patient has developed secondary myelodysplasia while t...

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (20)

  1. Gertz MA. Waldenstr€ om macroglobulinemia: 2013 update on diagnosis, risk stratification, and management. Am J Hematol. 2013; 88(8):703-711.
  2. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
  3. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009; 113(18):4163-4170.
  4. Leblebjian H, Agarwal A, Ghobrial I. Novel treatment options for Waldenstr€ om macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013;13(Suppl 2): S310-S316.
  5. Dimopoulos MA, Kastritis E, Owen RG, et al. Treatment recommendations for patients with Waldenstr€ om macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014;124(9):1404-1411.
  6. Dimopoulos MA, Zervas C, Zomas A, et al. Extended rituximab therapy for previously untreated patients with Waldenstr€ om's macroglobulinemia. Clin Lymphoma. 2002; 3(3):163-166.
  7. Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenstr€ om macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004;45(10): 2047-2055.
  8. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene. 2007;26( 25):3629-3636.
  9. Roccaro AM, Leleu X, Sacco A, et al. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2008;111(9): 4752-4763.
  10. Leleu X, Eeckhoute J, Jia X, et al. Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood. 2008;111(10):5068-5077.
  11. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res. 2007;13(11): 3320-3325.
  12. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Castritis E, Bitsaktsis A, Pangalis GA. Treatment of relapsed or refractory Waldenstr€ om's macroglobulinemia with bortezomib. Haematologica. 2005; 90(12):1655-1658.
  13. Chen CI, Kouroukis CT, White D, et al; National Cancer Institute of Canada Clinical Trials Group. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(12):1570-1575.
  14. Dimopoulos MA, Garc ıa-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and ritux- imab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122(19):3276-3282.
  15. Fine JP, Gray RJ. A proportional hazards model for the sub distribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
  16. Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant. 2010;45(9):1388-1395.
  17. Treon SP, Meid K, Gustine J, et al. Long-term outcome of a prospective study of bortezomib, dexamethasone and rituximab (BDR) in previously untreated, symptomatic patients with Waldenstrom's macroglobulinemia [abstract].
  18. Blood. 2015;126(23). Abstract 1833.
  19. Buske C, Hoster E, Dreyling M, et al.; German Low-Grade Lymphoma Study Group. The addi- tion of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a ran- domized trial of the German Low-Grade Lym- phoma Study Group (GLSG). Leukemia. 2009; 23(1):153-161.
  20. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstr€ om's macroglobulinemia. N Engl J Med. 2015;372(15): 1430-1440.